R&D to Revenue
38.81%
Fiscal year · Period ending:

ONC R&D to Revenue
What is r&d to revenue?
R&D spending as percentage of revenue.
ONC r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 38.806% | |
| 51.2643% | |
| 72.3365% | |
| 115.8615% | |
| 124.0551% | |
| 419.225% | |
| 216.5605% | |
| 342.5512% | |
| 112.8493% | |
| 9,161.9626% | |
| 660.7305% | |
| 167.7177% | |
| 120.7661% |
Frequently asked questions: ONC r&d to revenue
What is BeOne Medicines AG (ONC)'s current r&d to revenue?
BeOne Medicines AG (ONC)'s latest reported r&d to revenue (Fiscal year) is 38.81% as of Dec 31, 2025. R&D spending as percentage of revenue.
How much historical r&d to revenue data is available for ONC?
Stock Alarm Pro provides 13 dated annual fiscal periods observations for BeOne Medicines AG (ONC)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.
How can I compare ONC's r&d to revenue to peers or set an alert?
You can open ONC's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on ONC delivered by push, email, or phone call.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance